PHILADELPHIA, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced that the research group headed by Dr. H. Hasegawa, Chief, Laboratory of Mucosal Vaccine Development Virus Research Center, Japanese National Institute of Infectious Diseases (JIID), expanded the data on Ampligen(R), an experimental immunotherapeutic, in the Oct. 23, 2009, issue of Vaccine (Vol. 27, issue 45, pp 6276-6279) to include the conveyance of cross-protective immunity against various variants of the pandemic influenza virus. Dr. Hasegawa is the Principal Investigator on the Ampligen(R)/ Influenza vaccine program under the joint auspices of JIID/ Ministry of Health, Biken Corporation (Osaka) and Hemispherx Biopharma.
